SE9901272D0 - New improved formulation - Google Patents

New improved formulation

Info

Publication number
SE9901272D0
SE9901272D0 SE9901272A SE9901272A SE9901272D0 SE 9901272 D0 SE9901272 D0 SE 9901272D0 SE 9901272 A SE9901272 A SE 9901272A SE 9901272 A SE9901272 A SE 9901272A SE 9901272 D0 SE9901272 D0 SE 9901272D0
Authority
SE
Sweden
Prior art keywords
new improved
improved formulation
pharmaceutical formulations
bisphosphonate
osteoporosis
Prior art date
Application number
SE9901272A
Other languages
English (en)
Inventor
Lennart Lindfors
Jan-Erik Loefroth
Sven Sjoegren
Anna-Lena Ungell
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9901272A priority Critical patent/SE9901272D0/sv
Publication of SE9901272D0 publication Critical patent/SE9901272D0/sv
Priority to JP2000610444A priority patent/JP2002541185A/ja
Priority to KR1020017012793A priority patent/KR20010104389A/ko
Priority to NZ514478A priority patent/NZ514478A/xx
Priority to PCT/SE2000/000664 priority patent/WO2000061111A1/en
Priority to EP00921288A priority patent/EP1171097A1/en
Priority to IL14550600A priority patent/IL145506A0/xx
Priority to CA002364659A priority patent/CA2364659A1/en
Priority to AU41619/00A priority patent/AU4161900A/en
Priority to NO20014895A priority patent/NO20014895L/no
Priority to ZA200108260A priority patent/ZA200108260B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
SE9901272A 1999-04-09 1999-04-09 New improved formulation SE9901272D0 (sv)

Priority Applications (11)

Application Number Priority Date Filing Date Title
SE9901272A SE9901272D0 (sv) 1999-04-09 1999-04-09 New improved formulation
AU41619/00A AU4161900A (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
PCT/SE2000/000664 WO2000061111A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
KR1020017012793A KR20010104389A (ko) 1999-04-09 2000-04-06 비스포스포네이트 및 비스포스포네이트의 흡수를향상시키는 첨가제를 포함하는 제약 제제
NZ514478A NZ514478A (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
JP2000610444A JP2002541185A (ja) 1999-04-09 2000-04-06 ビスホスホネート及びビスホスホネートの吸収の向上をもたらす添加剤からなる医薬処方物
EP00921288A EP1171097A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
IL14550600A IL145506A0 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
CA002364659A CA2364659A1 (en) 1999-04-09 2000-04-06 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate
NO20014895A NO20014895L (no) 1999-04-09 2001-10-08 Farmasöytisk formulering innbefattende et bisfosfonat og et additivmiddel som gir foröket adsorpsjon av bisfosfonatet
ZA200108260A ZA200108260B (en) 1999-04-09 2001-10-08 A pharmaceutical formulation comprising an bisphosphonate and an additive agent providing an enhanced absorption of the bisphosphonate.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9901272A SE9901272D0 (sv) 1999-04-09 1999-04-09 New improved formulation

Publications (1)

Publication Number Publication Date
SE9901272D0 true SE9901272D0 (sv) 1999-04-09

Family

ID=20415159

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9901272A SE9901272D0 (sv) 1999-04-09 1999-04-09 New improved formulation

Country Status (11)

Country Link
EP (1) EP1171097A1 (sv)
JP (1) JP2002541185A (sv)
KR (1) KR20010104389A (sv)
AU (1) AU4161900A (sv)
CA (1) CA2364659A1 (sv)
IL (1) IL145506A0 (sv)
NO (1) NO20014895L (sv)
NZ (1) NZ514478A (sv)
SE (1) SE9901272D0 (sv)
WO (1) WO2000061111A1 (sv)
ZA (1) ZA200108260B (sv)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
EP1267890A2 (en) * 2000-04-07 2003-01-02 The Board of Regents of The University of Texas System Unique compositions of zwitterionic phospholipids and bisphosphonates and use of the compositions as bisphosphate delivery systems with reduced gi toxicity
MXPA02010740A (es) * 2000-05-05 2003-03-10 Hoffmann La Roche Composicion farmaceutica similar al gel para la administracion subcutanea que comprende acidos bisfosfonicos o sus sales.
CA2438848C (en) 2001-03-01 2011-05-03 Emisphere Technologies, Inc. Compositions for delivering bisphosphonates
WO2003003999A2 (en) * 2001-07-02 2003-01-16 Elan Corporation, Plc. Delivery of a bioactive material
PL399493A1 (pl) 2002-05-10 2012-11-05 F. Hoffmann-La Roche Ag Kwasy bisfosfonowe do leczenia i profilaktyki osteoporozy
ES2291749T5 (es) 2002-12-20 2011-07-21 F. Hoffmann-La Roche Ag Formulación de altas dosis de ibandronato.
ATE402942T1 (de) * 2003-01-17 2008-08-15 Teva Pharma Verfahren zur reduzierung des eisengehalts bei risedronat natrium
GB0310919D0 (en) * 2003-05-13 2003-06-18 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US8637503B2 (en) 2003-05-16 2014-01-28 Board Of Regents, The University Of Texas System Phenothiazine enantiomers as agents for the prevention of bone loss
US20080286359A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
RU2359678C2 (ru) * 2004-05-24 2009-06-27 Дзе Проктер Энд Гэмбл Компани Лекарственные формы на основе бисфосфонатов
US20080287400A1 (en) 2004-05-24 2008-11-20 Richard John Dansereau Low Dosage Forms Of Risedronate Or Its Salts
US7645459B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of bisphosphonates
US7645460B2 (en) 2004-05-24 2010-01-12 The Procter & Gamble Company Dosage forms of risedronate
WO2006020009A1 (en) * 2004-07-23 2006-02-23 The Procter & Gamble Company Solid oral dosage form of a bisphosphonate containing a chelating agent
KR100815040B1 (ko) * 2005-01-31 2008-03-18 주식회사종근당 비스포스포네이트계 약물의 경구흡수 개선을 위한약제학적 조성물
NO20053519L (no) * 2005-07-18 2007-01-19 Thia Medica As Anvendelse av forbindelser som omfatter fettsyrer
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
GB0616794D0 (en) 2006-08-24 2006-10-04 Arrow Int Ltd Solid dosage form
KR20110007242A (ko) 2008-05-07 2011-01-21 메리온 리서치 Ⅲ 리미티드 펩티드 조성물 및 그의 제조 방법
JP5421366B2 (ja) 2008-07-21 2014-02-19 オトノミ―，インク． 制御放出性の耳の構造体調節および生来の免疫システム調節化合物および耳の障害の処置のための方法
KR101631243B1 (ko) * 2009-05-13 2016-06-17 신일제약주식회사 신규한 알렌드로네이트 에멀젼 건조물의 제조 방법 및 이를 함유한 약제학적 조성물
ES2650665T3 (es) 2009-07-31 2018-01-19 Grünenthal GmbH Método de cristalización y biodisponibilidad
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
FR2954320B1 (fr) 2009-12-17 2012-06-15 Cll Pharma Composition pharmaceutique orale suprabiodisponible contenant un acide biphosphonique ou un de ses sels
WO2011120033A1 (en) 2010-03-26 2011-09-29 Merrion Research Iii Limited Pharmaceutical compositions of selective factor xa inhibitors for oral administration
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
WO2012094598A2 (en) 2011-01-07 2012-07-12 Merrion Research Iii Limited Pharmaceutical compositions of iron for oral administration
KR20120105738A (ko) * 2011-03-16 2012-09-26 현대약품 주식회사 장용코팅된 경구용 제제
JP5874545B2 (ja) * 2011-06-20 2016-03-02 アステラス製薬株式会社 経口投与用医薬組成物
CN107205948B (zh) 2015-01-29 2021-12-14 诺和诺德股份有限公司 包含glp-1激动剂和肠溶衣的片剂
WO2017007777A2 (en) * 2015-07-06 2017-01-12 Zhengxin Dong NOVEL FORMULATIONS OF PTHrP ANALOGUE
EP3455229B1 (en) * 2016-05-13 2021-03-24 Thar Pharma LLC Novel crystalline forms
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis
CN112972400A (zh) * 2021-03-09 2021-06-18 华侨大学 可快速崩解的米诺膦酸颗粒及制备方法
KR20240013402A (ko) * 2022-07-22 2024-01-30 주식회사 아이큐어비앤피 테리파라타이드를 포함하는 골다공증 예방 또는 치료를 위한 경구용 약학적 조성물 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8618259D0 (en) * 1986-07-25 1986-09-03 Leo Pharm Prod Ltd Pharmaceutical compositions
EP0550385A1 (de) * 1991-12-19 1993-07-07 Ciba-Geigy Ag Peroral zu verabreichende pharmazeutische Zusammensetzungen, die Methandiphosphonsäure-Derivate und 18-Krone-6 Ether enthalten
TW237386B (sv) * 1992-04-15 1995-01-01 Ciba Geigy
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE59300688D1 (de) * 1993-05-15 1995-11-02 Boehringer Mannheim Gmbh Tablette mit verbesserter Bioverfügbarkeit enthaltend Dichlormethylendiphosphonsäure als Wirkstoff.
IL118422A0 (en) * 1995-06-02 1996-09-12 Merck & Co Inc Use of alendronate for the prevention of osteoporosis
GB9516268D0 (en) * 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
GB9710699D0 (en) * 1997-05-24 1997-07-16 Danbiosyst Uk Gastro-retentive controlled release system
FI109088B (sv) * 1997-09-19 2002-05-31 Leiras Oy Tablett och förfarande för dess framställning
SE9703691D0 (sv) * 1997-10-10 1997-10-10 Astra Ab Pharmaceutical compositions

Also Published As

Publication number Publication date
AU4161900A (en) 2000-11-14
CA2364659A1 (en) 2000-10-19
ZA200108260B (en) 2003-03-26
EP1171097A1 (en) 2002-01-16
WO2000061111A1 (en) 2000-10-19
NZ514478A (en) 2004-01-30
NO20014895D0 (no) 2001-10-08
IL145506A0 (en) 2002-06-30
JP2002541185A (ja) 2002-12-03
NO20014895L (no) 2001-12-10
KR20010104389A (ko) 2001-11-24

Similar Documents

Publication Publication Date Title
SE9901272D0 (sv) New improved formulation
SE9703691D0 (sv) Pharmaceutical compositions
ATE232874T1 (de) Prostaglandin-konjugate zur behandlung von knochenkrankheiten
BR0016058A (pt) Compostos de fosfonato
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
SI1663185T1 (sl) Preprečevanje in zdravljenje z vnetjem inducirane in/ali imunsko posredovane izgube kosti
AR020345A1 (es) Pirazol-carboxanilidas, procedimiento para su obtencion, composiciones, empleo de dichos compuestos y procedimiento para la lucha contra microorganismos indeseables, y procedimiento para la obtencion de dichas composiciones.
AP9901478A0 (en) Compounds for the treatment of ischemia.
PL373903A1 (en) A combination of an nmda-antagonist and acetylcholine esterase inhibitors for the treatment of alzheimer's disease
HUP0004271A2 (hu) Elhízás kezelésére szolgáló, amilint vagy amilin-agonistát tartalmazó készítmények
DK0679393T3 (da) Pharmaceutisk præparat til behandling af osteoporose indeholdende xanthohumol
DE50004334D1 (de) Desodoriende zubereitungen enthaltend wasserlösliche -(1,3)-glucane
WO2001030333A3 (en) Tissue factor antagonists and methods of use thereof
TR199902703T2 (xx) Proteaz inhibit�rleri.
DE69730796D1 (de) Naphthylverbindungen, Zusammensetzungen und Verfahren
DE69905214D1 (de) Mittel zur Behandlung der Osteoporose
AU2003211610A1 (en) Pharmaceutical compositions for the treatment or prevention of osteoporosis
TWI262791B (en) 6-methoxy-2-naphthylacetic acid prodrugs
DE69831737D1 (de) Neurotrypsin
ATE263566T1 (de) Medizinische zusammensetzungen zur behandlung von knochenschäden im multiplen myelom
ATE245637T1 (de) Benzothiophenverbindungen, zubereitungen und verfahren
ATE244230T1 (de) Dihydrobenzofluorenverbindungen, zwischenprodukte,zusammensetzungen und methode
FR2783518B1 (fr) Inhibiteurs de lta4 hydrolase
MXPA03006468A (es) Composiciones para la prevencion o tratamiento de hepatopatia.
TWI226833B (en) Pharmaceutical composition for inhibiting bone resorption